Land: Irland
Sprache: Englisch
Quelle: HPRA (Health Products Regulatory Authority)
PIPERACILLIN TAZOBACTAM
Clonmel Healthcare Ltd
PIPERACILLIN TAZOBACTAM
2/0.250 Grams
Pdr for Soln Inj/Inf
Product subject to prescription which may not be renewed (A)
Withdrawn
2009-12-22
IRISH MEDICINES BOARD ACTS 1995 AND 2006 MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007 (S.I. NO.540 OF 2007) PA0126/180/001 Case No: 2070456 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to CLONMEL HEALTHCARE LIMITED WATERFORD ROAD, CLONMEL, CO. TIPPERARY, IRELAND an authorisation, subject to the provisions of the said Regulations, in respect of the product PIPERCIN 2 G/0.25 G POWDER FOR SOLUTION FOR INJECTION OR INFUSION The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 30/10/2009 until 12/02/2014. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 17/11/2009_ _CRN 2070456_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Pipercin 2g/0.25g Powder for Solution for Injection or Infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 2 g piperacillin (as sodium salt) and 0.25 g tazobactam (as sodium salt). One vial of powder for solution for injection or infusion contains 4.7 mmol (108 mg) of sodium. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Powder for solution for injection or infusion. White to off white powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Piperacillin/tazobactam is indicated for the treatment of moderate to severe syst Lesen Sie das vollständige Dokument